Navrogen

Leading the Way in Humoral Immuno-Oncology

At Navrogen, our team of experts is striving to provide innovative solutions to overcome immunosuppressive mechanisms at play in the Humoral Immuno-Oncology space.

Publications Pipeline

Visit us at AACR 2024
Poster Sessions
April 8, 9:00 am
April 9, 1:30 pm

OUR MISSION

Translating Clinical Knowledge Into Innovation

Our mission is to develop therapeutic agents that can overcome the immunosuppressive effects of factors that suppress humoral immune responses produced by tumors as well as develop diagnostic tools that can identify these factors in patients’ tumors to guide physicians on new therapeutic options

Poster Presentation

The ADC NAV-001 targets mesothelin, deploys a novel payload, and is refractory to CA125 inhibition

Poster Presentation

BRITE Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression

Publication

Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding

OUR PIPELINE

Discover How Our BRITE and HIO Screening Platforms Allowed Us to Develop a Unique Pipeline

Navrogen is pursuing a novel approach by targeting immunosuppressive pathways affecting humoral immunity.

Dr. Jeffrey V. Ravetch

Navrogen’s discovery of HIO factors will help us understand how tumors evade humoral immunity

Dr. Manish Patankar

News & Events

$Navrogen Presents Its Anti-CD20 Antibody NAV-006 and ICAM-1 Refractory Antibody-Drug Conjugate Platform at the 2024 American Association for Cancer Research Conference$

April 4, 2024

Navrogen Presents Its Anti-CD20 Antibody NAV-006 and ICAM-1 Refractory Antibody-Drug Conjugate Platform at the 2024 American Association for Cancer Research Conference

<strong>Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers</strong>“></p>
<p class= May 18, 2023

Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers

Navrogen Presents Preclinical Data on NAV-001 Antibody-Drug Conjugate and NAV-003 Bispecific Programs at the 2023 American Association for Cancer Research Meeting

April 12, 2023

Navrogen Presents Preclinical Data on NAV-001 Antibody-Drug Conjugate and NAV-003 Bispecific Programs at the 2023 American Association for Cancer Research Meeting